The two patients in the present cohort who received gefitinib/osimertinib/afatinib and trastuzumab/lapatinib, respectively represent the second and third cases of patients with listeria infections related to inhibitors of the EGFR/HER2 pathway. This evidence concerns the gene ERBB2 and listeriosis.